Endometrial cancer is considered according to statistics the most common gynecological tumor developed countries and observed that its incidence has been increasing. Historically, endometrial carcinoma is classified into two clinicopathological and molecular types: type I (endometrioid adenocarcinoma) is the most common and occurs in 80-90% of cases, type II comprises non-endometrioid subtypes such as serous, clear and undifferentiated carcinomas cells. An important fact is that most patients are diagnosed when the disease is in the early stages, ie when the lesion is still confined to the uterus. Conventional treatment lies in a bilateral salpingo-oophorectomy more primary hysterectomy, either through an abdominal laparotomy or using minimally invasive methods such as laparoscopy or robot-assisted laparoscopy. Resection of lymph nodes will depend on histological factors, stage of disease, patient characteristics and national and international guidelines for the management of this type of disease. With regard to this adjuvant treatment should be tailored to histology and tumor stage. Due to the large amount of literature available that deals with the management of endometrial cancer, the aim of this study was to perform a brief update on the disease in relation to diagnosis and treatment, based on a series of questions that were considered clinically relevant and that they have generated controversy for this purpose. By a search strategy in the database MEDLINE, EMBASE, PubMed, ClinicalKey, Ovid and Cochrane library; Using keywords, endometrial, diagnosis and treatment until 2016. In addition a number of controversial questions about diagnosis and treatment of endometrial cancer were formulated, based on which different keys to solving these questions words were used.